Custom Criteria for
BlueCross Blue Shield of Rhode Island Commercial

ZYTIGA (abiraterone)

GPI CODING:

21406010200320

DESCRIPTION:

Zytiga, in combination with prednisone, is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel. Zytiga is an oral androgen biosynthesis inhibitor that inhibits the CYP17 enzyme. This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis.

APPROVAL DURATION:

Approval duration: 1 year

CRITERIA FOR ZYTIGA

I. Patient has a diagnosis of prostate cancer that is metastatic and castration-resistant **AND**
II. Patient received prior chemotherapy containing docetaxel **AND**
III. Zytiga is used in combination with prednisone

OR

IV. Off label uses for oncology drugs if considered medically acceptable in one or more of the following compendia (i.e., Micromedex DrugDex, AHFS, Clinical Pharmacology, and NCCN.)) A use is identified by a compendium as medically accepted if the:
    A. Indication is a Category 1 or 2A in NCCN,
    B. Indication is a Class I, Class IIa or Class IIb in DrugDex,
    C. Narrative text in AHFS or Clinical Pharmacology is supportive; or
    D. The use is supported by clinical research in 2 or more peer-reviewed medical journals